In our 2020 book, ‘Longevity Industry 1.0: Defining the Biggest and Most Complex Industry in Human History’, we distilled the complex assembly of deep market intelligence and industry knowledge that Deep Knowledge Group and its Longevity-focused subsidiaries (including Longevity.Capital and Aging Analytics Agency) have developed over the past 7 years into a full-scope understanding of the global Longevity Industry.
That book placed particular emphasis on the power that Biomarkers of Human Longevity have to serve as a major catalyst and accelerator of short-term practical applications, and the translation of theory into practice, across almost every major aspect, domain and driving force of the Global Longevity MegaTrend, from business to scientific R&D, personal health optimization and Practical Human Longevity, the Longevity Financial Industry, investment decision-making, Longevity Industrialization and Longevity Politics, Policy and Governance. Both the increasing amount of tangible developments that have occurred within this domain since the release of ‘Longevity Industry 1.0’ in September 2020, as well as the systematically increasing need for Longevity Industry participants and stakeholders of all kinds - scientists, entrepreneurs, investors, financiers and policy-makers to being on-boarding and utilizing Biomarkers of Human Longevity within their strategic decision-making processes, has led to the decision that the time has come for a dedicated book on this topic.
Biomarkers of Human Longevity - Foreword by Dmitry Kaminskiy
There is perhaps no other single technology or industry subsector, with the exception of AI, that has more potential to accelerate the realization of real-world impacts in Longevity across the full scope of its sectors and domains - industry, policy, investment, entrepreneurship, policy and governance - than Biomarkers of Human Longevity. It is, quite literally, the key to achieving substantial real-world impact in the translation of Longevity theory into practice in the next several years, applying equally to individuals, scientists, entrepreneurs, investors and even governments.
Similarly, there are few other technologies and industry driving factors that find themselves the subject of so many differing opinions in terms of what should be definitionally encompassed by Biomarkers of Longevity, how they should be aggregated and validated both on an individual and population level, and how they can or should be applied in practice, both logistically, as well as with what specific end goals and practical impacts in mind.
Given the unique confluence of Biomarkers of Human Longevity’s disruptive impact and accelerative potential, on the one hand, and the high degree of disharmonization in terms of what they are and how they could and should be used, on the other hand, it is clear to me that there is a pressing unmet need for the production of a dedicated book that takes Biomarkers of Longevity as its central concern and major fulcrum, identifying the true potential that this technology has to increase individual and national Health-Adjusted Life Expectancy (HALE) and Quality-Adjusted Life Expectancy (QALY), optimize strategic decision-making for start-ups and corporations and investment decision-making for investors, and pave the way for a much more tangible, stable and scalable Global Longevity Industry, in which the socially-inclusive humanitarian impact of Longevity is maximized, and potential ethical and socioeconomic concerns and neutralized.
Deep Knowledge Group and its Longevity-focused subsidiaries and affiliates, including its analytical subsidiary Aging Analytics Agency, its specialized investment arm Longevity.Capital, its portfolio companies Longevity Banking Card and Longevity Financial Advisors and the international non-profit consortium Longevity.International, have prioritized the pressing need and the extreme potential of Biomarkers of Human Longevity (and integrated them in various ways into its overall scope of activities and strategic agenda) for several years now, and are expertly positioned to provide a tangible understanding of the major challenges and opportunities to be faced within this domain, and how they can be applied by individuals, institutions and even entire governments in order to achieve their maximum benefits while neutralizing potential pitfalls and issues.
In this book, I will distill the major conclusions, frameworks and forecasts developed and applied by Deep Knowledge Group on this matter with the overall aim of sharing some of our own key principles on how this technology can be effectively applied to optimize strategic decision-making, showing exactly how Biomarkers of Human Longevity is one of the most prospective market-ready tools for achieving tangible short-term results in personal Practical Human Longevity, making tangible Longevity investment decision-making and de-risking, re-tuning the business models of financial corporations (insurance companies, pension funds, and investment banks) at the intersection of the Opposed MegaTrends of Aging Population vs National Healthy Longevity.
2010-2020: Evolution of the Longevity Industry from Zero to 1.0
Data Science for Accelerating Aging Research, The Critical Catalyst for Practical Human Longevity and Tangible Investment De-Risking
The Industrialization of Longevity
The Current State of Longevity Science, Business, Finance, and Practical Applications
Longevity Becomes National Priority Item for the Strategic Agenda of Progressive Governments
Transforming the Challenge and Deficit of Aging into the Opportunity and Asset of Longevity
Defining and De-Risking: Hype vs. Reality
Modern Tools for Human Validation Results and De-Risking Investment Decision Making
SpaceTech and Space Medicine as a Modern Precedent for Safe and Effective Human Experimentation and Therapeutic Validation in the Longevity Industry
Longevity Economy 2.0 — Biomarkers of Human Longevity as Major Catalyst for Investment, InsurTech, Longevity Stock Exchange and Financial Instruments
Towards the Concept of a Comprehensive Digital Human Avatar 1.0, 2.0 and 3.0
Chapter 1: Biomarkers of Human Longevity as the Industry’s Major Critical Catalyst for Accelerating Practical Results in Aging Research Needed for Industry Growth
Chapter 1 presents an overview of the ways in which Biomarkers of Human Longevity will serve as the major catalyst for short-term change, development and harmonization within the Longevity Industry, capable of optimizing the strategies and practices of Longevity companies, investors and policy makers and enabling the first tangible, real-world impacts in the translation of Longevity science and theory into practice of Healthy Human Longevity.
Chapter 2: The Longevity Industry’s Fundamental and Systemic Risk: Reliance on Animal Model (Mouse) Results for Investment Due Diligence, Decision Making and Valuations
Chapter 2 presents an analysis of the Longevity Industry’s foremost fundamental and systemic risk and potential source of future destabilization (over reliance on animal validation data), which lays the necessary background and context for the third article in this series, which will provide an overview of how Biomarkers of Human Longevity, in integral combination with other modern tools, techniques and technologies, can be used to neutralize this source of risk, and pave the way for more stable and balanced developmental prospects for the future of the Global Longevity Industry.
The number of Longevity companies going public continues to grow: AgeX Therapeuytics (AGE), resTORbio, Inc. (TORC), Unity Biotechnology, Inc. (UBX), Athersys (ATHX), CohBar, Inc. (CWBR), Lineage Cell Therapeutics, Inc. (LCTX), Frequency Therapeutics (FREQ), Proteostasis Therapeutics, Inc. (PTI), Vericel Corporation (VCEL), Biophytis (ALBS.PA), with a number of others (e.g. Human Longevity Inc., Juvenescence, etc.) having announced plans to do so. As the volume of public capital, and the number of retail investors gaining exposure to the Longevity Industry, continues to grow, the problem of early positive results in model organisms not translating into positive human results in clinical trials becomes an increasingly prominent risk for overall industry sustainability, and the continued positive trajectory of overall investor sentiment.
Chapter 3: A Proposed Solution to The Longevity Industry’s Biggest Risk: Modern Tools for Safe Human Validation to De-Risk Investment Decision Making & IPOs
Chapter 3 outlines an integrated set of modern technological and scientific approaches and the framework for a proposed solution to the problem outlined in Chapter 2, which can allow for safe and effective human-centered validation of Longevity therapies and technologies at the pre-clinical trial phase, and which can be used by investors to de-risk their investment decision-making in this sector, by Longevity companies to more reliably validate the safety and efficacy of their therapeutic pipelines, and by Longevity startups preparing to launch IPOs to prevent dramatic declines in their market capitalization following failures for their model organism results to translate to humans.
Chapter 4: SpaceTech and Space and Sport Medicine as a Modern Precedent for Safe and Effective Human Experimentation and Therapeutic Validation in the Longevity Industry
Chapter 4 discusses the domains of Space and Sport Medicine as a modern precedent for safe and effective human experimentation and validation, exploring the lessons that can be learned and applied by the Longevity Industry, to facilitate a paradigm shift away from almost complete reliance on the results of model organism studies for due diligence, company valuation and investment decision making, and towards a more realistic, relevant and modern human-centered approach. It also addresses some interesting scientific and technological convergences between aging and the negative effects of spaceflight, and the ways in which the specific therapeutic approaches used to protect and preserve the health of astronauts intersect with Practical Healthy Human Longevity, as well as how advanced medicine is used to enhance extra performance in sport.
Multidimensional, longitudinal assays of the NASA Twins Study. (Left and middle) Genetically identical twin subjects (ground and flight) were characterized across 10 generalized biomedical modalities before (preflight), during (inflight), and after flight (postflight) for a total of 25 months (circles indicate time points at which data were collected). (Right) Data were integrated to guide biomedical metrics across various “-omics” for future missions (concentric circles indicate, from inner to outer, cytokines, proteome, transcriptome, and methylome).
Chapter 5: Longevity Economy 2.0: Biomarkers of Human Longevity as the Major Catalyst for Investment, InsurTech, Longevity Stock Exchange and Financial Instruments
Chapter 5 presents an analysis of the ways in which the financial industry in particular can on-board the approaches outlined in preceding chapters, relating both to Biomarkers of Human Longevity, and to modern, sophisticated approaches and solutions to safe Human experimentation and validation of Longevity therapies, and the ways in which these two worlds (the science and technology or Practical Human Longevity, and the global Financial Industry) intersect. It also charts the specific scope of investment and financial approaches required to truly transform these practices from tools being used by a small minority of Longevity investors (like Deep Knowledge Group, Deep Knowledge Ventures and Longevity.Capital) into industry standard practices to the mutual benefit of investors, companies, the general public and the entire industry itself.
Chapter 6: The Future of Biomarkers of Human Longevity: Towards the Concept of a Comprehensive Digital Human Avatar 1.0, 2.0 and 3.0
Chapter 6 synthesizes the full scope of topics and approaches outlined throughout the book, and chats how they are all quickly moving towards a future that would enable the synergetic and comprehensive integration of all data points impacting quality of life, performance, health and wealth into what can be determined a Digital Human Avatar - a full-scope, full-system model of the human body and mind, which can serve as the ideal tool for the optimization and predictive forecasting of health, wealth, wellness and performance, and for the high-frequency validation, adjustment and re-tuning of all internal and external factors impacting length and quality of life.
About the Author
Mr. Kaminskiy serves as managing trustee of Biogerontology Research Foundation, the UK’s oldest Longevity focused charity, and Head of International Development of the Longevity International UK - the Secretariat for the UK All-Party Parliamentary Group for Longevity, the world’s first official parliamentary group specifically dedicated to Longevity.
Dmitry Kaminskiy is an innovative entrepreneur, investor, author and philanthropist dedicated to impact investment and ethical business, with a focus on engineering the accelerated trajectory of progressive technological development for the benefit of humanity.
Mr. Kaminskiy is a co-founder and managing partner of Deep Knowledge Group - a consortium of commercial and non-profit organizations active on many fronts in the realm of DeepTech and Frontier Technologies (AI, Longevity, Precision Medicine, FinTech, GovTech, InvestTech), ranging from scientific research to investment, entrepreneurship, analytics, policy and philanthropy.
He leads the activities of the consortium’s venture arms - Deep Knowledge Ventures, an investment fund focused on DeepTech and advanced science projects, and Longevity.Capital, which prioritizes the convergence of Longevity and Artificial Intelligence, areas in which it has unparalleled investment and exit strategies.
He is a frequent speaker on the topics of AI and Longevity, including conferences organized in London by The Economist “Aging Societies and The Business of Longevity”, Financial Times “Smart Machines vs Smart People”, at the Future Finance Forum in Seoul “AI in Finance”, “Precision Medicine World Conference" in Silicon Valley, as well as several others at Oxford and Cambridge Universities.